The risks of inhaled corticosteroid withdrawal in COPD treatment
Previous trials on triple therapy inhaler use (ETHOS and IMPACT) were understood to show a reduction in mortality in COPD patients. However, a reanalysis published in Thorax shows that this benefit may have been misattributed. Host Dr. Kate Diomede is joined by the paper's authors, pharmacist Kari Leung¹ and physician Prof. Aroon Hingorani², both members of the North Central London Joint Formulary committee.
Read the paper: Inhaled corticosteroid withdrawal and mortality rate in trials of triple therapy inhalers for COPD
Further reading: Withdrawal of fluticasone propionate from combined…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.